Janssen Prods Drug Patent Portfolio

Janssen Prods owns 7 orange book drugs protected by 54 US patents with Edurant Ped having the least patent protection, holding only 2 patents. And Prezista with maximum patent protection, holding 26 patents. Given below is the list of Janssen Prods's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10786518 Compositions and methods of treating HIV 19 Jul, 2038
Active
US11065198 Dispersible compositions 23 Oct, 2037
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
Active
US8148399 Macrocyclic inhibitors of hepatitis C virus 05 Sep, 2029
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
Active
US8895557 Pharmaceutical formulations of ecteinascidin compounds 07 Jul, 2028
Active
US8895557 Pharmaceutical formulations of ecteinascidin compounds 07 Jan, 2028
Active
US7700645 Pseudopolymorphic forms of a HIV protease inhibitor 26 Jun, 2027
Active
US7700645 Pseudopolymorphic forms of a HIV protease inhibitor 26 Dec, 2026
Active
US8349869 Macrocylic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US8741926 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US8754106 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US9040562 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US9353103 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US9623022 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US9856265 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Oct, 2025
Active
US7671032 HCV NS-3 serine protease inhibitors 19 May, 2025
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
Active
US8518987 Pseudopolymorphic forms of a HIV protease inhibitor 16 Aug, 2024 Expired
US8518987 Pseudopolymorphic forms of a HIV protease inhibitor 16 Feb, 2024 Expired
US7638522 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile 14 Apr, 2023 Expired
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023 Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022 Expired
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022 Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021 Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021 Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020 Expired
US7470506 Fitness assay and associated methods 23 Dec, 2019 Expired
US8597876 Method of treating HIV infection 23 Dec, 2019 Expired
US9889115 Fitness assay and associated methods 23 Dec, 2019 Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019 Expired
US7470506 Fitness assay and associated methods 23 Jun, 2019 Expired
US8597876 Method of treating HIV infection 23 Jun, 2019 Expired
US9889115 Fitness assay and associated methods 23 Jun, 2019 Expired
USRE43596 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 09 Nov, 2017 Expired
USRE43596 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 09 May, 2017 Expired
USRE42889 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Apr, 2017 Expired
USRE43802 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Apr, 2017 Expired
US6037157 Method for improving pharmacokinetics 26 Dec, 2016 Expired
US6703403 Method for improving pharmacokinetics 26 Dec, 2016 Expired
USRE42889 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Oct, 2016 Expired
USRE43802 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Oct, 2016 Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016 Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016 Expired
US5843946 α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 01 Jun, 2016 Expired
US5843946 α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 01 Dec, 2015 Expired
US6248775 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 13 Feb, 2015 Expired
US6248775 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 13 Aug, 2014 Expired
US6335460 α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors 25 Feb, 2013 Expired
US6335460 α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors 25 Aug, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Janssen Prods.

Activity Date Patent Number
Patent litigations
Expire Patent 22 Jan, 2024 US8080551
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8148374 (Litigated)
Maintenance Fee Reminder Mailed 07 Aug, 2023 US8080551
Payment of Maintenance Fee, 12th Year, Large Entity 12 Jul, 2023 US8101629
Expire Patent 25 Jul, 2022 US8754106
Expire Patent 11 Jul, 2022 US8741926
Payment of Maintenance Fee, 8th Year, Large Entity 06 Jul, 2022 US9040562
Payment of Maintenance Fee, 8th Year, Large Entity 25 May, 2022 US8895557
Expire Patent 21 Mar, 2022 US9889115
Expire Patent 21 Mar, 2022 US9889115
Maintenance Fee Reminder Mailed 07 Feb, 2022 US8754106
Expire Patent 07 Feb, 2022 US9856265
Payment of Maintenance Fee, 4th Year, Large Entity 26 Jan, 2022 US10039718
Maintenance Fee Reminder Mailed 24 Jan, 2022 US8741926
Expire Patent 10 Jan, 2022 US8597876 (Litigated)


Janssen Prods's Drug Patent Litigations

Janssen Prods's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Janssen Prods's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8518987 April, 2015 Terminated-Denied
(16 Oct, 2015)
Janssen Sciences Ireland UC Lupin Limited
US6703396 April, 2002 Decision
(04 Apr, 2002)
DIONNE
US6642245 July, 2001 Decision
(05 Jul, 2001)
DIONNE


Janssen Prods Drug Patents' Oppositions Filed in EPO

Janssen Prods drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 09, 2012, by Hamm, Volker. This opposition was filed on patent number EP05108086A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16180589A Oct, 2020 Cooke, Richard Granted and Under Opposition
EP16180589A Oct, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP16180589A Jan, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP14168686A Apr, 2018 Cooke, Richard Opposition rejected
EP13164300A Jan, 2018 Georg Kalhammer/Stephan Teipel Granted and Under Opposition
EP13164300A Jan, 2018 Aechter, Bernd Granted and Under Opposition
EP13164300A Jan, 2018 Cooke, Richard Granted and Under Opposition
EP12753867A Jul, 2017 FRKelly Granted and Under Opposition
EP12753867A Jul, 2017 Sandoz GmbH Granted and Under Opposition
EP12753867A Jul, 2017 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP12167591A May, 2017 Cooke, Richard Revoked
EP12167590A May, 2017 Cooke, Richard Revoked
EP12167590A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167591A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167589A May, 2017 Cooke, Richard Granted and Under Opposition
EP12167589A May, 2017 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP12167596A Apr, 2017 Cooke, Richard Revoked
EP12167596A Apr, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP09739981A Jun, 2016 Cooke, Richard Revoked
EP09739981A Jun, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP10703766A Apr, 2016 Cooke, Richard Revoked
EP10703766A Apr, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP07836007A Mar, 2016 Trösch, Dominique Granted and Under Opposition
EP07836007A Mar, 2016 Georg Kalhammer/Stephan Teipel Granted and Under Opposition
EP07836007A Mar, 2016 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP04787096A Jan, 2016 Page White & Farrer Limited Patent maintained as amended
EP01961695A Nov, 2015 HEXAL PHARMA AG Patent maintained as amended
EP01961695A Nov, 2015 Strawman Limited Patent maintained as amended
EP01961695A Nov, 2015 Teva Pharmaceutical Industries Ltd Patent maintained as amended
EP01961695A Nov, 2015 Swindell & Pearson Limited Patent maintained as amended
EP10180831A Mar, 2015 Wittkopp, Alexander Patent maintained as amended
EP03753571A Mar, 2015 Wittkopp, Alexander Patent maintained as amended
EP03753571A Mar, 2015 Strawman Limited Patent maintained as amended
EP10180831A Mar, 2015 Strawman Limited Patent maintained as amended
EP10180831A Mar, 2015 Alfred E. Tiefenbacher (GmbH & Co. KG) Patent maintained as amended
EP03753571A Mar, 2015 Alfred E. Tiefenbacher (GmbH & Co. KG) Patent maintained as amended
EP05108086A Feb, 2012 Hamm, Volker The patent has been limited


Janssen Prods's Family Patents

Janssen Prods drugs have patent protection in a total of 64 countries. It's US patent count contributes only to 13.0% of its total global patent coverage. 16 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Janssen Prods Drug List

Given below is the complete list of Janssen Prods's drugs and the patents protecting them.


1. Edurant

Edurant is protected by 7 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7125879
(Pediatric)
HIV inhibiting pyrimidines derivatives 21 Oct, 2025
(1 year, 11 days from now)
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
(6 months from now)
Active
US7638522 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile 14 Apr, 2023
(1 year, 5 months ago)
Expired
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023
(1 year, 5 months ago)
Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022
(2 years ago)
Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021
(3 years ago)
Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edurant's drug page


2. Edurant Ped

Edurant Ped is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11065198 Dispersible compositions 23 Oct, 2037
(13 years from now)
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edurant Ped's drug page


3. Olysio

Olysio is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8148399 Macrocyclic inhibitors of hepatitis C virus 05 Sep, 2029
(4 years from now)
Active
US8349869 Macrocylic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US8741926 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US8754106 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US9040562 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US9353103 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US9623022 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US9856265 Macrocyclic inhibitors of hepatitis C virus 28 Jul, 2026
(1 year, 9 months from now)
Active
US7671032 HCV NS-3 serine protease inhibitors 19 May, 2025
(7 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olysio's drug page


4. Prezcobix

Prezcobix is protected by 19 patents, out of which 15 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
(7 years from now)
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US7700645
(Pediatric)
Pseudopolymorphic forms of a HIV protease inhibitor 26 Jun, 2027
(2 years from now)
Active
US7700645 Pseudopolymorphic forms of a HIV protease inhibitor 26 Dec, 2026
(2 years from now)
Active
US8518987
(Pediatric)
Pseudopolymorphic forms of a HIV protease inhibitor 16 Aug, 2024
(a month ago)
Expired
US8518987 Pseudopolymorphic forms of a HIV protease inhibitor 16 Feb, 2024
(7 months ago)
Expired
US7470506
(Pediatric)
Fitness assay and associated methods 23 Dec, 2019
(4 years ago)
Expired
US8597876
(Pediatric)
Method of treating HIV infection 23 Dec, 2019
(4 years ago)
Expired
US7470506 Fitness assay and associated methods 23 Jun, 2019
(5 years ago)
Expired
US8597876 Method of treating HIV infection 23 Jun, 2019
(5 years ago)
Expired
US9889115 Fitness assay and associated methods 23 Jun, 2019
(5 years ago)
Expired
USRE43596
(Pediatric)
α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 09 Nov, 2017
(6 years ago)
Expired
USRE43596 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 09 May, 2017
(7 years ago)
Expired
USRE42889
(Pediatric)
α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Apr, 2017
(7 years ago)
Expired
USRE43802
(Pediatric)
α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Apr, 2017
(7 years ago)
Expired
USRE42889 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Oct, 2016
(7 years ago)
Expired
USRE43802 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Oct, 2016
(7 years ago)
Expired
US5843946
(Pediatric)
α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 01 Jun, 2016
(8 years ago)
Expired
US5843946 α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 01 Dec, 2015
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prezcobix's drug page


5. Prezista

Prezista is protected by 26 patents, out of which 24 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7700645
(Pediatric)
Pseudopolymorphic forms of a HIV protease inhibitor 26 Jun, 2027
(2 years from now)
Active
US7700645 Pseudopolymorphic forms of a HIV protease inhibitor 26 Dec, 2026
(2 years from now)
Active
US8518987
(Pediatric)
Pseudopolymorphic forms of a HIV protease inhibitor 16 Aug, 2024
(a month ago)
Expired
US8518987 Pseudopolymorphic forms of a HIV protease inhibitor 16 Feb, 2024
(7 months ago)
Expired
US7470506
(Pediatric)
Fitness assay and associated methods 23 Dec, 2019
(4 years ago)
Expired
US8597876
(Pediatric)
Method of treating HIV infection 23 Dec, 2019
(4 years ago)
Expired
US9889115
(Pediatric)
Fitness assay and associated methods 23 Dec, 2019
(4 years ago)
Expired
US7470506 Fitness assay and associated methods 23 Jun, 2019
(5 years ago)
Expired
US8597876 Method of treating HIV infection 23 Jun, 2019
(5 years ago)
Expired
US9889115 Fitness assay and associated methods 23 Jun, 2019
(5 years ago)
Expired
USRE43596
(Pediatric)
α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 09 Nov, 2017
(6 years ago)
Expired
USRE43596 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 09 May, 2017
(7 years ago)
Expired
USRE42889
(Pediatric)
α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Apr, 2017
(7 years ago)
Expired
USRE43802
(Pediatric)
α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Apr, 2017
(7 years ago)
Expired
US6037157
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6703403
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
USRE42889 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Oct, 2016
(7 years ago)
Expired
USRE43802 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 19 Oct, 2016
(7 years ago)
Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US5843946
(Pediatric)
α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 01 Jun, 2016
(8 years ago)
Expired
US5843946 α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 01 Dec, 2015
(8 years ago)
Expired
US6248775
(Pediatric)
α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 13 Feb, 2015
(9 years ago)
Expired
US6248775 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors 13 Aug, 2014
(10 years ago)
Expired
US6335460
(Pediatric)
α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors 25 Feb, 2013
(11 years ago)
Expired
US6335460 α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors 25 Aug, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prezista's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Symtuza

Symtuza is protected by 14 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10786518 Compositions and methods of treating HIV 19 Jul, 2038
(13 years from now)
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
(7 years from now)
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US7700645 Pseudopolymorphic forms of a HIV protease inhibitor 26 Dec, 2026
(2 years from now)
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
(6 months from now)
Active
US8518987 Pseudopolymorphic forms of a HIV protease inhibitor 16 Feb, 2024
(7 months ago)
Expired
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022
(2 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(3 years ago)
Expired
US7470506 Fitness assay and associated methods 23 Jun, 2019
(5 years ago)
Expired
US8597876 Method of treating HIV infection 23 Jun, 2019
(5 years ago)
Expired
US9889115 Fitness assay and associated methods 23 Jun, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symtuza's drug page


7. Yondelis

Yondelis is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8895557
(Pediatric)
Pharmaceutical formulations of ecteinascidin compounds 07 Jul, 2028
(3 years from now)
Active
US8895557 Pharmaceutical formulations of ecteinascidin compounds 07 Jan, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yondelis's drug page